This study assesses glucometric parameters and device satisfaction among adults with type 1 diabetes (T1D) using different treatment strategies in a real-world setting. It is a multicenter, cross-sectional study where participants were categorized based on treatment strategy: Multiple Daily Injections and Continuous Glucose Monitoring (MDI+CGM), Sensor Augmented Pump Therapy (SAP), Predictive Low Glucose Management (PLGM), and Automated Insulin Delivery (AID). The association of treatment strategies with glycemic outcomes was analyzed using logistic regression. Glucose Management Indicator (GMI), dichotomized at 7%, and Time In Glucose Range (TIR) 70-180 mg/dL, dichotomized at 70%, were the dependent variables, and treatment modalities, demographic, socioeconomic, and clinical characteristics were covariates. A total of 389 adults, 55% female, with a median age of 32 (IQR: 23-47) years, were recruited. Subjects treated with AID reported significantly higher TIR and lower time above 180 and 250 mg/dL than MDI+CGM and SAP (p<0.001). The coefficient of variation of average glucose was significantly lower in AID users compared to MDI+CGM and SAP users (p<0.001). Subjects treated with MDI+CGM had lower device satisfaction than those treated with SAP or AID (p<0.001). The probability of having GMI≤7% was 2.3 (95% CI: 1.3-4.1) times higher in adults treated with AID than in subjects treated with MDI+CGM, 65% (95%CI: 11-87%) lower in subjects with a low level of education than in subjects with a high level and increased of 2% (95%CI: 1-4%) per each year increase of age. The probability of having TIR≥70% was 3.7 (95%CI: 2.1-6.6) times higher in adults treated with AID than those treated with MDI+CGM. In adults with type 1 diabetes, AID allows for the better achievement of glycemic targets and higher device satisfaction. There is a need to implement educational programs to optimize the use of technology regardless of education level.